domenica, 3 maggio 2026

Notizie AIOM – anno XV

3 Febbraio 2017

Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial

Fentanyl sublingual tablets (FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain episodes. No direct comparison between FST and SCM is available. The aim of this study was to test noninferiority ...
Leggi tutto

3 Febbraio 2017

ASCO Clinical Practice Guideline on Management of Small Renal Masses

February 1st, 2017 - As reported in the Journal of Clinical Oncology by Antonio Finelli, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, ASCO has released a clinical practice guideline on management of small renal masses. The guideline was derived from an ...
Leggi tutto

3 Febbraio 2017

Immunotherapy 2.0 Named Advance of the Year in ASCO’s Report

February 1st, 2017 - A growing number of patients with cancer are benefiting from research advances in immunotherapy, leading ASCO to name immunotherapy as the Society's Advance of the Year for a second year in a row. Released today, Clinical Cancer Advances 2017: ASCO's ...
Leggi tutto

3 Febbraio 2017

ASH/AACR/AACI/ASTRO/ASPHO/Lungevity Foundation Statement on Administration’s Executive Order

February 1st, 2017 - “As the world's leading organizations representing laboratory researchers, physician-scientists, clinicians, the nation’s cancer centers, and patient advocates committed to improved care for patients with cancer and blood diseases, we express ...
Leggi tutto

3 Febbraio 2017

FDA Approves Nivolumab in Locally Advanced or Metastatic Bladder Cancer

February 2nd, 2017 - On February 2, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing ...
Leggi tutto

3 Febbraio 2017

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare ...
Leggi tutto

3 Febbraio 2017

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. ...
Leggi tutto

3 Febbraio 2017

30 gennaio 2017 – Joint Action europea sulle malattie croniche – Come prevenire, gestire e curare le malattie croniche per una vita sana e un invecchiamento attivo

3 Febbraio 2017

31 gennaio 2017 – Procedura di applicazione Managed Entry Agreement – medicinale Axitinib

3 Febbraio 2017

1 febbraio 2017 – Comitato per i Medicinali per Uso umano (CHMP) dell’EMA: highlights del meeting di gennaio